-
1 Comment
Sartorius Stedim Biotech S.A is currently in a long term uptrend where the price is trading 28.5% above its 200 day moving average.
From a valuation standpoint, the stock is 93.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.2.
Sartorius Stedim Biotech S.A's total revenue rose by 45.8% to $531M since the same quarter in the previous year.
Its net income has increased by 107.4% to $114M since the same quarter in the previous year.
Finally, its free cash flow fell by 84.4% to $8M since the same quarter in the previous year.
Based on the above factors, Sartorius Stedim Biotech S.A gets an overall score of 4/5.
ISIN | FR0013154002 |
---|---|
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
CurrencyCode | EUR |
Exchange | PA |
Market Cap | 18B |
---|---|
PE Ratio | 88.7 |
Target Price | 252.5 |
Dividend Yield | 0.4% |
Beta | 0.98 |
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for DIM.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025